Levetiracetam (Epilepsy)

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12824
R48268		 Thomas (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021 Cardiac malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.43 [0.14;14.07] C
excluded (control group) 		3/106   1/50 4 106
ref
S12823
R48258		 Thomas (Levetiracetam) (Controls unexposed, sick), 2021 Cardiac malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 1.07 [0.28;4.03] C 3/106   9/340 12 106
ref
S7651
R22631		 Tomson (Levetiracetam), 2018 Cardiac malformations at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.40 [0.51;3.87] C 5/599   15/2,514 20 599
ref
S5938
R23789		 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Cardiovascular anomalies 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No Controls: mixed indications 1.16 [0.12;11.15] C 1/450   3/1,562 4 450
ref
S6063
R15768		 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 Cardiac 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 3.32 [0.17;63.64] C 0/22   4/647 4 22
ref
Total 4 studies 1.33 [0.64;2.78] 40 1,177
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Levetiracetam) (Controls unexposed, sick), 2021Thomas, 2021 1 1.07[0.28; 4.03]1210631%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Tomson (Levetiracetam), 2018Tomson, 2018 2 1.40[0.51; 3.87]2059952%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012Hernández-Díaz, 2012 3 1.16[0.12; 11.15]445011%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 4 3.32[0.17; 63.64]4226%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 1.33[0.64; 2.78]401,1770.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam; 3: Levetiracetam) (Controls exposed to Lamotrigine, sick; 4: Levetiracetam) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.33[0.64; 2.78]401,1770%NAThomas (Levetiracetam) (Controls unexposed, sick), 2021 Tomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.07[0.28; 4.03]12106 -NAThomas (Levetiracetam) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 1.47[0.61; 3.56]281,0710%NATomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 3 Tags Adjustment   - No  - No 1.33[0.64; 2.78]401,1770%NAThomas (Levetiracetam) (Controls unexposed, sick), 2021 Tomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 4 Controls   - mixed indications  - mixed indications 1.16[0.12; 11.15]4450 -NAHernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 1 All studiesAll studies 1.33[0.64; 2.78]401,1770%NAThomas (Levetiracetam) (Controls unexposed, sick), 2021 Tomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 40.510.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.53.81.8080.000Thomas (Levetiracetam) (Controls unexposed, sick), 2021Tomson (Levetiracetam), 2018Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 12824

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.07[0.28; 4.03]12106 -NAThomas (Levetiracetam) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.47[0.64; 3.34]321,1770%NAThomas (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 40.510.01.0